After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through its $3.9 billion ...
Merck KGaA (ETR:MRK) executives told investors the company delivered “solid” organic growth in 2025 despite a challenging ...
Investing.com -- Merck KGaA (ETR:MRCG) on Thursday warned adjusted operating profit margins would shrink in 2026 as patent ...
Merck KGaA expects its 2026 adjusted operating profit to decrease by up to 4%, excluding currency effects, according to its latest statement.
Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple ...
Germany's Merck KGaA projected 2026 adjusted operating profit to slip by as much as 9.8%, hurt by negative currency effects and the loss of patent protection for a multiple sclerosis drug.
In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on ...
Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value CatalystsMarket News Updates News ...
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across ...
NORD Calls on Nation to "Show Your Stripes®" on Global Rare Disease Day®, Feb. 28NORWELL, Mass., Feb. 23, 2026 /PRNewswire/ - ...
Find insight on Merck KGaA and Granules India in the latest Market Talks covering the health care sector.
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results